Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Next-generation cytology test provides additional information for HPV-positive women who may have cervical pre-cancer
- More sensitive than Pap cytology testing when used as triage test for HPV-positive screening results, helping to improve the detection of cervical pre-cancer
- The first biomarker-based test specifically approved by the FDA to triage women with HPV-positive / Pap cytology-negative co-testing results, providing clinicians with a new option to guide patient management
- Launch supports the goal of the World Health Organization to eliminate cervical cancer,? which is nearly 100 percent preventable
Attachment